Cytotect® CP Biotest
CMV-spezifisches Immunglobulin vom Menschen zur intravenösen Anwendung

Referenzen (werden auf Verlangen abgegeben):

  1. Fachinformation Cytotect® CP Biotest: www.swissmedicinfo.ch
  2. EMEA Commitee for Propietary Medicinal Products; Note for Guidance on plasma-derived medicinal products; CPMP/BWP/269/95 1) (2001) rev. 3.
  3. www.pptaglobal.org/program/qseal.aspx
  4. Arzneimittelverordnung; Stand 01.10.2010: Abschnitt 5, Artikel 19.
  5. Burnouf T et al.: Heamophilia (2003) 9 (1): 24-37.
  6. Kotton C.N. et al.: The third international consensus guidelines on the managment of cytomegalovirus in solid-organ transplantation. Transplantation (2018) 102: 900-931.
  7. Snydman D.R. et al.: Update and review: State-of-the-art management of cytomegalovirus infection and disease following throacic organ transplantation. Transpl. Proceed. (2011) 43: 1-17.
  8. Schulz U. et al.: CMV immunoglobulins for the treatment of CMV infections in thoracic transplant recipients. Transplantation (2016) 100: 5-10.
  9. Rea F. et al.: Cytomegalovirus hyper immunoglobulin for CMV prophylaxis iin thoracic transplantation. Transplantation (2016) 100: 19-26.
  10. Carbone J. et al.: The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation (2016) 100: S11-S18.
  11. Grossi et al.: Cytomegalovirus immunoglobulin after thoracic transplantation: an overview. Transplantation (2016) 100: 1-4.
  12. Valantine H.A. et al.: Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation. Transplantation (2001) 72: 1647-1652.
  13. Ruttman E. et al.: Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation (2006) 81: 1415-1420.
  14. Carbone J. et al.: Potential immunomodulatory role of specific anticytomegalovirus intravenous immunoglobulin in heart recipients. Transpl. Proceed. (2016) 48: 3027-3029.
  15. Solidoro P. et al.: Effect of CMV-immunoglobulins (Cytotect Biotest) prophylaxis on CMV pneumonia after lung transplantation. New Microbiologica (2011) 34: 33-36.
  16. Potena L. et al.: Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation (2006) 82: 398-405.
  17. Germer et al. 2016: Functional properties of human cytomegalovirus hyperimmunoglobulin and standard immunoglobulin preparations. Annals of transplantation, 2016; 21: 558-564.